Takeda v. Alkem & Ascend: 17-Patent Colchicine Suit Voluntarily Dismissed After 5+ Years
Takeda Pharmaceutical asserted 17 patents covering its Colcrys® (colchicine, 0.6 mg) tablets against generic challengers Alkem Laboratories and Ascend Laboratories in Delaware. After more than 1,870 days of litigation, Takeda voluntarily dismissed the case before defendants had filed an answer or summary judgment motion — leaving the public record silent on merits and settlement terms.
Takeda’s 17-Patent Colcrys® Fortress Falls Quietly After Five Years
On 3 March 2020, Takeda Pharmaceutical Co., Ltd. filed suit in the Delaware District Court (Case No. 1:20-cv-00325) against Alkem Laboratories, Ltd. and Ascend Laboratories, LLC, asserting 17 U.S. patents covering its branded colchicine 0.6 mg oral tablet product, Colcrys®. The complaint arose in the context of an ANDA challenge — a standard Hatch-Waxman mechanism by which generic manufacturers seek FDA approval to market a bioequivalent product before listed patents expire. Judge Richard G. Andrews was assigned to preside over the matter.
On 16 April 2025, Takeda filed a notice of voluntary dismissal pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i), bringing the case to a close. The notice expressly states that defendants had neither answered the complaint nor filed a motion for summary judgment, satisfying the procedural prerequisite for a unilateral dismissal by the plaintiff. The public record does not specify whether the dismissal was with or without prejudice, and no settlement terms have been disclosed.
A case spanning 1,870 days — over five years — that ends in a plaintiff-initiated voluntary dismissal before any merits ruling is unusual and typically suggests a negotiated resolution, a commercial agreement outside the litigation, or a strategic reassessment of the patent portfolio’s enforceability. The precise driver cannot be confirmed from the docket alone. What remains unknown is whether Takeda extracted any licensing concessions, whether defendants agreed to delay market entry, or whether the dismissal reflects a broader portfolio strategy around colchicine IP.
Filing to Voluntary dismissal in 1870 days
1,870 days — over 5 years, well above the median ANDA patent trial in Delaware
Voluntarily dismissed: what the Rule 41 exit means for both parties
Rule 41(a)(1)(A)(i): plaintiff’s unilateral exit before answer
Federal Rule of Civil Procedure 41(a)(1)(A)(i) permits a plaintiff to dismiss a case without a court order if the defendant has not yet filed an answer or a summary judgment motion. Takeda’s notice confirms both conditions were met. This route requires no judicial approval and is effective immediately upon filing. Critically, the rule itself does not specify prejudice — the notice must do so, and the public record here is silent on that point.
Rule 41(a)(1)(A)(i) dismissalThe prejudice question: public record is silent
A dismissal ‘with prejudice’ extinguishes Takeda’s right to re-file on the same claims against these defendants; ‘without prejudice’ preserves that right. Under Rule 41(a)(1)(A)(i), if the notice is silent, courts generally treat it as without prejudice — but this is a default, not a certainty. The available docket text does not specify either characterisation, so practitioners should not assume either outcome without reviewing the full notice filing.
Prejudice status unconfirmedAlkem and Ascend: litigation risk removed, future exposure uncertain
With the case dismissed before any merits adjudication, Alkem and Ascend avoided a court ruling on infringement or validity of Takeda’s 17 colchicine patents. If the dismissal is without prejudice, Takeda could potentially re-file, meaning defendants may face continued IP risk if they launch their generic products. If a confidential agreement governs the exit, its terms — including any agreed launch date — would define the actual commercial outcome for both parties.
No merits ruling obtained17-patent ANDA shield: what survives the dismissal
Takeda’s 17-patent portfolio covering Colcrys® remains unchallenged on the merits by this court. No patent was found invalid or not infringed in this proceeding. For other generic entrants, this means the colchicine IP landscape is no clearer than before the suit — each of the 17 asserted patents retains its presumption of validity. Competitors and R&D teams monitoring colchicine market entry should treat this dismissal as inconclusive rather than as a green light.
Portfolio validity intactFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Takeda Pharmaceutical Co., Ltd. | Company | Global pharmaceutical company — holder of 17 colchicine (Colcrys®) patentsSearch in Eureka ↗ |
| Defendant | Alkem Laboratories, Ltd. | Company | Generic pharmaceutical manufacturers seeking ANDA approval for colchicine 0.6 mg tabletsSearch in Eureka ↗ |
| Co-Defendant | Ascend Laboratories, LLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | Edgar H. Haug | Attorney | Counsel for Takeda Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Francis DiGiovanni | Attorney | Counsel for Takeda Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Jonathan Herstoff | Attorney | Counsel for Takeda Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Porter F. Fleming | Attorney | Counsel for Takeda Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Thatcher A. Rahmeier | Attorney | Counsel for Takeda Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Faegre Drinker Biddle & Reath LLP | Law Firm | Representing Takeda Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | Adam Wyatt Poff | Attorney | Counsel for Alkem Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Samantha G. Wilson | Attorney | Counsel for Alkem Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Teresa M. Summers | Attorney | Counsel for Alkem Laboratories, Ltd.Search in Eureka ↗ |
| Defendant law firm | Young Conaway Stargatt & Taylor, LLP | Law Firm | Representing Alkem Laboratories, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i) and expressly states that defendants had not answered the complaint or filed a motion for summary judgment. This phrasing is a standard procedural recital confirming the unilateral dismissal right — it carries no implication of merit or fault. Critically, the notice does not specify ‘with prejudice’ or ‘without prejudice,’ leaving the re-filing question legally ambiguous. For practitioners, this means neither party can be said to have prevailed on the substantive patent questions.
US7915269B2 and 16 further patents — colchicine 0.6 mg oral tablet formulations
The 17 patents asserted by Takeda collectively cover the formulation, composition, dosing, and methods of use of colchicine 0.6 mg oral tablets as marketed under the Colcrys® brand. Colchicine is an established anti-inflammatory agent used to treat acute gout flares and Familial Mediterranean Fever (FMF). The asserted patents span application dates from approximately 2008 through 2012, reflecting Takeda’s layered IP strategy to build a multi-patent barrier around the branded product following FDA’s 2009 approval of Colcrys® as the first FDA-approved single-ingredient oral colchicine product in the U.S.
The breadth of the 17-patent portfolio — covering not only the formulation itself but also methods of administration, drug interaction management, and dosing protocols — reflects a classic evergreening strategy in pharmaceutical IP. Each additional patent layer extends the effective exclusivity horizon and raises the cost and complexity of ANDA challenges. For competing generic manufacturers and their IP counsel, the portfolio represents one of the more densely layered small-molecule colchicine IP thickets in the U.S. market, making clearance analysis particularly demanding.
Should you run an FTO against Takeda’s 17 colchicine patents?
Any company developing, manufacturing, or seeking FDA approval for a generic colchicine 0.6 mg oral tablet product should treat Takeda’s 17-patent portfolio as active IP risk. The voluntary dismissal of this case produced no invalidity or non-infringement finding — every patent retains its statutory presumption of validity. R&D teams, regulatory affairs professionals, and in-house IP counsel working on colchicine ANDAs should conduct a structured FTO review covering all 17 asserted patents before committing to a Paragraph IV certification strategy.
PatSnap Eureka’s FTO Search Agent enables rapid mapping of all 17 asserted colchicine patents — including claim scope, application histories, and expiry dates adjusted for patent term adjustments. Eureka can identify which claims pose the highest infringement risk for a given formulation approach and flag any post-grant proceedings that may have narrowed claim scope. For teams preparing ANDA filings or evaluating launch-at-risk decisions, Eureka provides the analytical foundation needed to make defensible strategic calls.
Run a freedom-to-operate analysis on US7915269B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman colchicine patent cases in U.S. district courts
Cases involving Colcrys® colchicine patents and ANDA generic challenges in Delaware and other U.S. district courts with comparable multi-patent pharmaceutical portfolios.
What this case signals for the colchicine and ANDA patent IP landscape
A five-year ANDA suit ending in silent voluntary dismissal carries significant signals for generic entry strategy and branded pharmaceutical IP enforcement.
17 colchicine patents remain untested: validity risk persists for all ANDA filers
No court ruled on the validity or infringement of any of Takeda’s 17 asserted patents. Generic manufacturers entering or considering the colchicine 0.6 mg space must still contend with this portfolio as live IP risk. An FTO analysis across all 17 patents is essential before any generic product launch decision.
Silent voluntary dismissal after 5 years is a strong signal of off-docket resolution
Hatch-Waxman cases rarely run for 1,870 days and terminate silently without a trial or summary judgment ruling. This pattern is broadly consistent with a confidential settlement, a consent judgment with agreed launch date, or a licensing arrangement — none of which are visible on the public docket. Parties tracking Colcrys® market dynamics should monitor FDA ANDA approval records for launch date signals.
Takeda v Alkem — key questions answered
Takeda asserted 17 U.S. patents covering colchicine 0.6 mg oral tablet formulations and methods of use under the Colcrys® brand, including US7915269B2, US7601758B1, US8093297B2, US7964648B2, US8415396B1, US7906519B2, US8093296B2, US7820681B1, US8415395B1, US8093298B2, US7935731B2, US8097655B2, US7964647B2, US7619004B1, US8440722B2, US7981938B2, and US8440721B2.
The public record does not disclose Takeda’s reasons. A voluntary dismissal after over five years of litigation — before any merits ruling — is broadly consistent with a confidential settlement, a licensing agreement, an agreed generic launch date, or a strategic portfolio reassessment. No settlement terms or confidential agreements are visible on the docket.
Not necessarily. The dismissal notice does not specify whether it was with or without prejudice. If without prejudice, Takeda could potentially re-file. If a confidential agreement governs the exit, any agreed launch date would control. Generic launch eligibility also depends on FDA ANDA approval status and the terms of any off-docket arrangement between the parties.
No. The case was dismissed voluntarily before defendants answered the complaint or filed for summary judgment. No court ruling on the validity, enforceability, or infringement of any of the 17 asserted patents was issued. All 17 patents retain their statutory presumption of validity.
Rule 41(a)(1)(A)(i) allows a plaintiff to dismiss a case without court order if the defendant has not yet answered or moved for summary judgment. It takes effect immediately upon filing and requires no judicial approval. If the notice is silent on prejudice — as it appears to be here — courts generally apply a default of without prejudice, though practitioners should confirm by reviewing the full notice text.
PatSnap Eureka searches patents and litigation data to answer instantly.